Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma
Background
Nivolumab is an immune checkpoint inhibitor (ICI) that selectively inhibits programmed cell death protein 1 activation, restoring antitumor immunity. ICIs are indicated for various types of advanced solid tumors; however, not all patients b…